282 related articles for article (PubMed ID: 32035924)
1. Imiquimod Exerts Antitumor Effects by Inducing Immunogenic Cell Death and Is Enhanced by the Glycolytic Inhibitor 2-Deoxyglucose.
Huang SW; Wang ST; Chang SH; Chuang KC; Wang HY; Kao JK; Liang SM; Wu CY; Kao SH; Chen YJ; Shieh JJ
J Invest Dermatol; 2020 Sep; 140(9):1771-1783.e6. PubMed ID: 32035924
[TBL] [Abstract][Full Text] [Related]
2. Targeting aerobic glycolysis and HIF-1alpha expression enhance imiquimod-induced apoptosis in cancer cells.
Huang SW; Kao JK; Wu CY; Wang ST; Lee HC; Liang SM; Chen YJ; Shieh JJ
Oncotarget; 2014 Mar; 5(5):1363-81. PubMed ID: 24658058
[TBL] [Abstract][Full Text] [Related]
3. ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death.
Zhang Y; Guo C; Liu L; Xu J; Jiang H; Li D; Lan J; Li J; Yang J; Tu Q; Sun X; Alamgir M; Chen X; Shen G; Zhu J; Tao J
Theranostics; 2020; 10(24):11197-11214. PubMed ID: 33042278
[No Abstract] [Full Text] [Related]
4. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P
Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822
[TBL] [Abstract][Full Text] [Related]
5. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod-induced ROS production causes lysosomal membrane permeabilization and activates caspase-8-mediated apoptosis in skin cancer cells.
Chang SH; Lin PY; Wu TK; Hsu CS; Huang SW; Li ZY; Liu KT; Kao JK; Chen YJ; Wong TW; Wu CY; Shieh JJ
J Dermatol Sci; 2022 Sep; 107(3):142-150. PubMed ID: 36075780
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod-induced ROS production disrupts the balance of mitochondrial dynamics and increases mitophagy in skin cancer cells.
Chuang KC; Chang CR; Chang SH; Huang SW; Chuang SM; Li ZY; Wang ST; Kao JK; Chen YJ; Shieh JJ
J Dermatol Sci; 2020 Jun; 98(3):152-162. PubMed ID: 32376151
[TBL] [Abstract][Full Text] [Related]
8. Imiquimod activates p53-dependent apoptosis in a human basal cell carcinoma cell line.
Huang SW; Chang SH; Mu SW; Jiang HY; Wang ST; Kao JK; Huang JL; Wu CY; Chen YJ; Shieh JJ
J Dermatol Sci; 2016 Mar; 81(3):182-91. PubMed ID: 26775629
[TBL] [Abstract][Full Text] [Related]
9. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
Cho JH; Lee HJ; Ko HJ; Yoon BI; Choe J; Kim KC; Hahn TW; Han JA; Choi SS; Jung YM; Lee KH; Lee YS; Jung YJ
Oncotarget; 2017 Apr; 8(15):24932-24948. PubMed ID: 28212561
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of Imiquimod enhanced ALA-PDT on cutaneous squamous cell carcinoma.
Bhatta AK; Wang P; Keyal U; Zhao Z; Ji J; Zhu L; Wang X; Zhang G
Photodiagnosis Photodyn Ther; 2018 Sep; 23():273-280. PubMed ID: 30030167
[TBL] [Abstract][Full Text] [Related]
11. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.
Aspord C; Tramcourt L; Leloup C; Molens JP; Leccia MT; Charles J; Plumas J
J Invest Dermatol; 2014 Oct; 134(10):2551-2561. PubMed ID: 24751730
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy with doxorubicin and caffeine combination enhanced ICD induction and T-cell infiltration in B16F10 melanoma tumors.
Yerragopu AK; Vellapandian C
J Biochem Mol Toxicol; 2023 May; 37(5):e23327. PubMed ID: 36807623
[TBL] [Abstract][Full Text] [Related]
13. Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment.
Shen N; Wu J; Yang C; Yu H; Yang S; Li T; Chen J; Tang Z; Chen X
Nano Lett; 2019 Nov; 19(11):8021-8031. PubMed ID: 31558024
[TBL] [Abstract][Full Text] [Related]
14. Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity.
Sethuraman SN; Singh MP; Patil G; Li S; Fiering S; Hoopes PJ; Guha C; Malayer J; Ranjan A
Theranostics; 2020; 10(8):3397-3412. PubMed ID: 32206098
[No Abstract] [Full Text] [Related]
15. Imiquimod-oleic acid prodrug-loaded cream reduced drug crystallinity and induced indistinguishable cytotoxicity and apoptosis in mice melanoma tumour.
Sharma A; Sharma D; Baldi A; Jyoti K; Chandra R; Madan J
J Microencapsul; 2019 Dec; 36(8):759-774. PubMed ID: 31587598
[TBL] [Abstract][Full Text] [Related]
16. The copper (II) complex of salicylate phenanthroline induces immunogenic cell death of colorectal cancer cells through inducing endoplasmic reticulum stress.
Chen M; Wang D; Fan L; Niu D; Xu J; Liu Y; Liu Y
Int Immunopharmacol; 2024 May; 132():111980. PubMed ID: 38555819
[TBL] [Abstract][Full Text] [Related]
17. The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Jia H; Ren W; Feng Y; Wei T; Guo M; Guo J; Zhao J; Song X; Wang M; Zhao T; Wang H; Feng Z; Tian Z
Int J Oncol; 2018 Sep; 53(3):949-960. PubMed ID: 30015838
[TBL] [Abstract][Full Text] [Related]
18. 4-(N)-Docosahexaenoyl 2', 2'-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent.
Hufnagel S; Xu H; Colemam MF; Valdes SA; Liu KA; Hursting SD; Cui Z
Cancer Chemother Pharmacol; 2022 Jan; 89(1):59-69. PubMed ID: 34698902
[TBL] [Abstract][Full Text] [Related]
19. An ER-Targeting Iridium(III) Complex That Induces Immunogenic Cell Death in Non-Small-Cell Lung Cancer.
Wang L; Guan R; Xie L; Liao X; Xiong K; Rees TW; Chen Y; Ji L; Chao H
Angew Chem Int Ed Engl; 2021 Feb; 60(9):4657-4665. PubMed ID: 33217194
[TBL] [Abstract][Full Text] [Related]
20. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.
Dewan MZ; Vanpouille-Box C; Kawashima N; DiNapoli S; Babb JS; Formenti SC; Adams S; Demaria S
Clin Cancer Res; 2012 Dec; 18(24):6668-78. PubMed ID: 23048078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
